Collectively, our findings suggest that specific targeting of PLT SYK might be a promising therapeutic approach to treat thrombocytopenia and thrombosis in VITT, and possibly in other Fc-RIIA–mediated immune thrombotic diseases. This evidence concerns the gene SYK and Thrombocytopenia.